Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | IDE | P14735 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9352176 | 0.74 | MEN1 (0.46) | MEN1USP2MAPTKMT2APOLB | |
| SCHEMBL27661935 | 0.74 | MEN1 (0.37) | MEN1USP2MAPTKMT2APOLB | |
| SCHEMBL11330344 | 0.63 | — | — | |
| SCHEMBL6013334 | 0.63 | MEN1 (0.39) | MEN1USP2MAPTKMT2APOLB | |
| SCHEMBL9351124 | 0.63 | MEN1 (0.38) | MEN1USP2MAPTKMT2APOLB | |
| SCHEMBL1032396 | 0.63 | MEN1 (0.35) | MEN1USP2MAPTKMT2APOLB | |
| SCHEMBL9620152 | 0.62 | MEN1 (0.31) | MEN1USP2MAPTKMT2APOLB | |
| SCHEMBL3713097 | 0.61 | — | — | |
| SCHEMBL31711471 | 0.60 | MAPT (0.47) | MEN1USP2MAPTKMT2APOLB | |
| SCHEMBL7485753 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106139158-A | The growth hormone that in vivo efficacy extends | 诺沃—诺迪斯克保健股份有限公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-105963710-A | Growth hormones with prolonged in-vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-103215328-B | The joint of transglutaminase mediated peptide | 诺和诺德医疗保健公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-101130526-B | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK AS | 2013-07-10 | — | — | CN | disclosed |
| US-8378097-B2 | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| CN-101142194-B | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors | TRANSTECH PHARMA INC | 2012-10-10 | — | — | CN | disclosed |
| CN-102612376-A | Growth hormone with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG | 2012-07-25 | — | — | CN | disclosed |
| CN-102295606-A | Method of combining 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine,and applicable intermediates thereof its salts and solvates and its use as histamine h3 receptor antagonist | — | 2011-12-28 | — | — | CN | disclosed |
| CN-1494425-B | carboxamide derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2011-12-07 | — | — | CN | disclosed |
| CN-101410385-B | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC | 2011-08-24 | — | — | CN | disclosed |
| CN-1909930-A | Transglutaminase mediated conjugation of peptides | NOVO NORDISK AS (DK) | 2007-02-07 | — | — | CN | disclosed |
| CN-1886365-A | Novel salicylanilides | NOVO NORDISK AS (DK) | 2006-12-27 | — | — | CN | disclosed |
| CN-1832920-A | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA INC (US) | 2006-09-13 | — | — | CN | disclosed |
| CN-1235583-C | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA INC (US) | 2006-01-11 | — | — | CN | disclosed |
| CN-1678311-A | Arylcarbonyl derivatives useful as therapeutic agents | NOVO NORDISK AS (DK) | 2005-10-05 | — | — | CN | disclosed |
| CN-1658871-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2005-08-24 | — | — | CN | disclosed |
| CN-1633290-A | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2005-06-29 | — | — | CN | disclosed |
| CN-1494423-A | Benzimidazole derivatives as therapeutic agents | 特兰斯泰克制药公司 | 2004-05-05 | — | — | CN | disclosed |
| CN-1494425-A | Carboxamide derivatives as therapeutic agents | 特兰斯泰克制药公司 | 2004-05-05 | — | — | CN | disclosed |
| CN-1278794-A | Substituted 2-hydroxyindole derivatives as inhibitors of protein tyrosine kinases and protein serine/threonine kinases | GLAXO GROUP LTD (GB) | 2001-01-03 | — | — | CN | disclosed |